SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-24-049432
Filing Date
2024-04-29
Accepted
2024-04-29 07:00:44
Documents
11
Period of Report
2024-06-20

Document Format Files

Seq Description Document Type Size
1 DEF 14A final_-_2024_proxy.htm DEF 14A 606482
2 GRAPHIC img206406122_0.jpg GRAPHIC 2785
3 GRAPHIC img206406122_1.jpg GRAPHIC 3916
4 GRAPHIC img206406122_2.jpg GRAPHIC 1414
5 GRAPHIC img206406122_3.jpg GRAPHIC 3916
6 GRAPHIC img206406122_4.jpg GRAPHIC 23785
7 GRAPHIC img206406122_5.jpg GRAPHIC 23785
8 GRAPHIC img206406122_6.jpg GRAPHIC 23785
9 GRAPHIC img206406122_7.jpg GRAPHIC 1414
10 GRAPHIC img206406122_8.jpg GRAPHIC 646766
11 GRAPHIC img206406122_9.jpg GRAPHIC 538417
  Complete submission text file 0000950170-24-049432.txt   2356005
Mailing Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141
Business Address 140 FIRST STREET, SUITE 501 CAMBRIDGE MA 02141 (617) 949-4360
Omega Therapeutics, Inc. (Filer) CIK: 0001850838 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40657 | Film No.: 24886541
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)